5 Nov 2014 06:10
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
BTG Share News (BTG)
BTG Share
Price
BTG Share
News
BTG Share
Chat
BTG Share
Trades
BTG
Live RNS
BTG Share
Charts
BTG Broker
Ratings
BTG Directors
Deals
BTG Financial
Diary
BTG
Fundamentals
BTG Short
Positions
BTG
Media
BTG Information
- There is currently no data for BTG
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.BTG's interim profit soars thanks to solid growth across the board
Tue, 10th Nov 2015 08:03
(ShareCast News) - Healthcare group BTG has posted an increase in interim pre-tax profit, boosted by solid growth across all of its divisions.In the six months to 30 September, the FTSE 250 group posted a 40.6% year-on-year increase in pre-tax profit to £52.9m, while revenue rose 20% to £229.6m.The company said the first full six-month contribution from its acquisition of PneumRx, which was completed in January this year, delivered an important boost to its results, as did continued growth across its four business segments.The group's interventional medicine division posted a 36% year-on-year rise in revenue, while the interventional vascular segment and the licensing division posted a 40% and 31% gain respectively and the speciality pharmaceuticals registered a marginal increase."We have had a good first half, delivering double-digit revenue and contribution growth from our portfolio of products while increasing investment in our Interventional Medicine business," said group chief executive Louise Makin.The group said it remains on track to deliver double-digit revenue growth for the full year and was aiming at making for investments in the future.BTG shares were down 4.76% to 520.00p at 0823 GMT on Tuesday.
More News
4 Nov 2014 16:15
21 Oct 2014 14:38
FTSE 250 movers: Retail stocks lead rise as footfall decline slows
Retail stocks were putting in a strong performance on Tuesday after data from BRC-Springboard showed the decline in UK retail footfall eased to 0.9% in September from a 1.1% drop in August. Stocks such as Debenhams, Home Retail, Just Eat, WH Smith and Halfords were all in positive territory. "With a
Read more14 Oct 2014 09:17
Tuesday broker round-up UPDATE
Anglo Pacific: FinnCap upgrades to buy with a target price of 158p. Peel Hunt shifts target price from 196p to 198p retaining its buy recommendation. Ashmore: Canaccord Genuity upgrades from sell to hold with a target price of 300p. Numis cuts target price from 369p to 355p retaining an add rating.
Read more13 Oct 2014 09:32
Monday broker round-up UPDATE
Amino Technologies: Northland Capital upgrades to buy with a target price of 100p. Anglo American: Canaccord Genuity initiates with a target price of 1720p and a buy recommendation. Credit Suisse upgrades to outperform with a target price of 1800p. Associated British Foods: Societe Generale upgrade
Read more13 Oct 2014 07:58
BTG to sell two drug treatments directly to 11 European countries
Healthcare group BTG has announced its plans to start selling two of its oncology treatments directly to 11 European countries from 1 April next year. The move comes after the FTSE 250 group earlier this year began building a direct sales force to promote the approved uses of its products in major E
Read more10 Oct 2014 15:13
FTSE 250 movers: Telecom Plus climbs as oil stocks slide
Utility services group Telecom Plus said it is happy with market expectations for the full year after strong organic growth in the first half, causing shares to surge on Friday. The company said that the strong growth in both customers and service numbers seen at the start of the year accelerated in
Read more10 Oct 2014 12:29
BTG to pay $6m to settle legal dispute with Bioclon over snake venom drug
Specialist healthcare company BTG has settled its US patent infringement complaint against Instituto Bioclon and Rare Disease Therapeutics with a $6m payment. The FTSE 250-listed group has agreed to allow Bioclon to start selling its crotalid treatment from October 2018 if the Mexico-based firm rece
Read more9 Oct 2014 09:27
Thursday broker round-up UPDATE
African Barrick Gold: Numis reduces target price from 330p to 270p keeping its hold recommendation. Antofagasta: Numis upgrades to hold with a target price of 700p. Aureus Mining: Numis lowers target price from 45p to 40p staying with its buy recommendation. Boohoo: Barclays initiates with a targe
Read more